Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 1 | BMC Cancer

Figure 1

From: Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma

Figure 1

The metabolic response of patients with mRCC after 14 days treatment with tyrosine kinase inhibitors. (A) Waterfall plots of the metabolic response of patients with mRCC after 14 days of treatment with tyrosine kinase inhibitors as reflected in SULpeak, TLG75 and TLG50. Kaplan-meier graphs comparing responders and non-responders with regards to time to progression (B) and overall survival (C).

Back to article page